Seeking Partners in Development
EmeraMed is seeking strategic partners and investors to support the continued clinical development and potential commercialization of Emeramide (also known as NBMI or Irminix®). Emeramide is designed to bind irreversibly to certain heavy metals (such as mercury, arsenic, cadmium, lead, and others) and to address oxidative stress.
Emeramide (NBMI): Mercury Chelator Under FDA Review
Emeramide (Also known as Irminix®) is a lipophilic mercury chelator in development by EmeraMed, that is currently under FDA review as a treatment for mercury poisoning.
Warning: Counterfeit Emeramide sold illegally in EU & USA
Counterfeit Emeramide is being sold under our various trade names (OSR#1, NBMI, Emeramide) and tests have shown that it is not Emeramide. This is unsafe and illegal and we are continuously in contact with various regulatory authorities to take action.


